Prohibit Restrictions on 340B Drugs
| Type | Bill |
|---|---|
| Session | 2025 Regular Session |
| Subjects |
Concerning certain practices by persons participating in the supply chain of drugs purchased under the federal 340B drug pricing program.
Bill Summary:
Under the federal 340B drug pricing program (340B program), a covered entity, including certain hospitals, programs, and federally qualified health centers (covered entity), that serves patients with low income receives discounted outpatient drugs (340B drugs) from manufacturers that participate in the federal medicaid and medicare programs. Unless the receipt of 340B drugs is prohibited by the federal department of health and human services, the act prohibits a manufacturer, third-party logistics provider, or repackager in this state, or an agent, contractor, or affiliate of those entities, including an entity that collects or processes health information, from directly or indirectly denying, restricting, prohibiting, discriminating against, or otherwise limiting the acquisition of a 340B drug by, or delivery of a 340B drug to, a covered entity, a pharmacy contracted with a covered entity, or a location otherwise authorized by a covered entity to receive and dispense 340B drugs.
The act also prohibits a manufacturer from directly or indirectly requiring a covered entity, a pharmacy contracted with a covered entity, or any other location authorized to receive 340B drugs by a covered entity to submit any health information, claims or utilization data, or other specified data that does not relate to a claim submitted to certain federal health care programs, unless the data is voluntarily furnished or required to be furnished under federal law.
The act defines "340B savings" as the difference between the aggregated market rate costs and the aggregated acquisition costs for 340 B drugs. Certain hospital covered entities are prohibited from using 340B savings for certain purposes.
A violation of the prohibitions in the act is an unfair or deceptive trade practice under the "Colorado Consumer Protection Act" (protection act), and the violator is subject to the enforcement provisions and penalties contained in the protection act. In addition, a person regulated by the state board of pharmacy (pharmacy board) that violates the provisions of the protection act may be subject to discipline by the pharmacy board against the person's license, certification, or registration, as well as other penalties.
The act requires certain hospital covered entities to annually report to the department of health care policy and financing certain information concerning 340B savings and costs relating to providing charity care.
(Note: This summary applies to this bill as enacted.)
Related Documents & Information
| Activity | Vote | Documents |
|---|---|---|
| Refer Senate Bill 25-071 to the Committee of the Whole. | The motion passed on a vote of 12-1. | Vote summary |
| Activity | Vote | Documents |
|---|
| Activity | Vote | Documents |
|---|---|---|
| Adopt amendment L.002 (Attachment H). | The motion passed without objection. | Vote summary |
| Adopt amendment L.003 (Attachment I). | The motion passed without objection. | Vote summary |
| Adopt amendment L.001 (Attachment J). | The motion passed without objection. | Vote summary |
| Refer Senate Bill 25-071, as amended, to the Committee of the Whole. | The motion passed on a vote of 7-2. | Vote summary |
| Date | Calendar | Motion | Vote | Vote Document |
|---|---|---|---|---|
| 05/06/2025 | Third Reading | BILL |
57
AYE
8
NO
0
OTHER
|
Vote record |
| 05/05/2025 | Committee of the Whole | AMD (H.001) |
17
AYE
47
NO
1
OTHER
|
Vote record |
| Date | Calendar | Motion | Vote | Vote Document |
|---|---|---|---|---|
| 03/26/2025 | Third Reading | BILL |
30
AYE
4
NO
1
OTHER
|
Vote record |
| Date | Amendment Number | Committee/ Floor Hearing | Status | Documents |
|---|---|---|---|---|
| 05/05/2025 | H.001 | Committee of the Whole | Lost | |
| 05/05/2025 | L.027 | Second Reading | Lost [**] | |
| 05/05/2025 | L.029 | Second Reading | Lost [**] | |
| 03/25/2025 | L.017 | Second Reading | Passed [**] | |
| 03/25/2025 | L.016 | Second Reading | Passed [**] | |
| 03/13/2025 | L.001 | SEN Health & Human Services | Passed [*] | |
| 03/13/2025 | L.003 | SEN Health & Human Services | Passed [*] | |
| 03/13/2025 | L.002 | SEN Health & Human Services | Passed [*] |
| Date | Location | Action |
|---|---|---|
| 05/30/2025 | Governor | Governor Signed |
| 05/15/2025 | Governor | Sent to the Governor |
| 05/15/2025 | House | Signed by the Speaker of the House |
| 05/15/2025 | Senate | Signed by the President of the Senate |
| 05/06/2025 | House | House Third Reading Passed - No Amendments |
| 05/05/2025 | House | House Second Reading Special Order - Passed - No Amendments |
| 05/03/2025 | House | House Committee on Health & Human Services Refer Unamended to House Committee of the Whole |
| 04/30/2025 | House | House Committee on Health & Human Services Witness Testimony and/or Committee Discussion Only |
| 03/26/2025 | House | Introduced In House - Assigned to Health & Human Services |
| 03/26/2025 | Senate | Senate Third Reading Passed - No Amendments |
| 03/25/2025 | Senate | Senate Second Reading Passed with Amendments - Committee, Floor |
| 03/21/2025 | Senate | Senate Second Reading Laid Over to 03/25/2025 - No Amendments |
| 03/18/2025 | Senate | Senate Second Reading Laid Over to 03/21/2025 - No Amendments |
| 03/13/2025 | Senate | Senate Committee on Health & Human Services Refer Amended to Senate Committee of the Whole |
| 01/22/2025 | Senate | Introduced In Senate - Assigned to Health & Human Services |
Prime Sponsor
Sponsor
Co-Sponsor
| Effective Date | Chapter # | Title | Documents |
|---|---|---|---|
| 08/06/2025 | 313 | Prohibit Restrictions on 340B Drugs |